ArticleAntimicrobial agents and chemotherapy2024
Spectinamide MBX-4888A exhibits favorable lesion and tissue distribution and promotes treatment shortening in advanced murine models of tuberculosis.
Abstract read
In one paragraph
Article in Antimicrobial agents and chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Sterilizing activity of spectinamide MBX-4888A when replacing linezolid in the Nix-TB regimen in the relapsing BALB/c mouse model of tuberculosis.Antimicrobial agents and chemotherapy · 2025Article
- Establishing translational performance standards for TB therapy using rifampicin-based regimens in a male and female high-burden murine model.BMC microbiology · 2025Article
- Enhancing the therapeutic window for Spectinamide anti-tuberculosis Agents: Synthesis, Evaluation, and activation of phosphate prodrug 3408.Bioorganic & medicinal chemistry letters · 2024Article
Corrections and comments
- Update of
Authors and funding
25 authors.
Allison A BaumanDepartment of Microbiology, Immunology and Pathology, Mycobacteria Research Laboratories, Colorado State University, Fort Collins, Colorado, USA.
Jansy P SarathyHackensack Meridian School of Medicine, Center for Discovery and Innovation, Nutley, New Jersey, USA.ORCID 0000-0002-1532-146X
Firat KayaHackensack Meridian School of Medicine, Center for Discovery and Innovation, Nutley, New Jersey, USA.
Lisa M MassoudiDepartment of Microbiology, Immunology and Pathology, Mycobacteria Research Laboratories, Colorado State University, Fort Collins, Colorado, USA.
Michael S SchermanDepartment of Microbiology, Immunology and Pathology, Mycobacteria Research Laboratories, Colorado State University, Fort Collins, Colorado, USA.
Courtney HastingsDepartment of Microbiology, Immunology and Pathology, Mycobacteria Research Laboratories, Colorado State University, Fort Collins, Colorado, USA.
Jiuyu LiuDepartment of Chemical Biology & Therapeutics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Min XieHackensack Meridian School of Medicine, Center for Discovery and Innovation, Nutley, New Jersey, USA.ORCID 0000-0002-9770-5351
Elizabeth J BrooksDepartment of Microbiology, Immunology and Pathology, Mycobacteria Research Laboratories, Colorado State University, Fort Collins, Colorado, USA.
Michelle E RameyDepartment of Microbiology, Immunology and Pathology, Mycobacteria Research Laboratories, Colorado State University, Fort Collins, Colorado, USA.
Isabelle L JonesDepartment of Microbiology, Immunology and Pathology, Mycobacteria Research Laboratories, Colorado State University, Fort Collins, Colorado, USA.
Noalani D BenedictDepartment of Microbiology, Immunology and Pathology, Mycobacteria Research Laboratories, Colorado State University, Fort Collins, Colorado, USA.
Madelyn R MaclaughlinDepartment of Microbiology, Immunology and Pathology, Mycobacteria Research Laboratories, Colorado State University, Fort Collins, Colorado, USA.
Jake A Miller-DawsonDepartment of Microbiology, Immunology and Pathology, Mycobacteria Research Laboratories, Colorado State University, Fort Collins, Colorado, USA.
Samanthi L WaidyarachchiMicrobiotix, Inc., Worcester, Massachusetts, USA.
Michelle M ButlerMicrobiotix, Inc., Worcester, Massachusetts, USA.
Terry L BowlinMicrobiotix, Inc., Worcester, Massachusetts, USA.ORCID 0000-0002-9184-5791
Matthew D ZimmermanHackensack Meridian School of Medicine, Center for Discovery and Innovation, Nutley, New Jersey, USA.
Anne J LenaertsDepartment of Microbiology, Immunology and Pathology, Mycobacteria Research Laboratories, Colorado State University, Fort Collins, Colorado, USA.
Bernd MeibohmDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Sciences Center, Memphis, Tennessee, USA.ORCID 0000-0003-3923-3648
Mercedes Gonzalez-JuarreroHackensack Meridian School of Medicine, Center for Discovery and Innovation, Nutley, New Jersey, USA.ORCID 0000-0002-4045-2365
Michael A LyonsDepartment of Microbiology, Immunology and Pathology, Mycobacteria Research Laboratories, Colorado State University, Fort Collins, Colorado, USA.ORCID 0000-0003-0143-6626
Veronique DartoisHackensack Meridian School of Medicine, Center for Discovery and Innovation, Nutley, New Jersey, USA.ORCID 0000-0001-9470-5009
Richard E LeeDepartment of Chemical Biology & Therapeutics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Gregory T RobertsonDepartment of Microbiology, Immunology and Pathology, Mycobacteria Research Laboratories, Colorado State University, Fort Collins, Colorado, USA.ORCID 0000-0001-7157-4034
Funding
Development of Novel Proteins Synthesis Inhibitors for MDR TuberculosisR01AI090810 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI LEE, RICHARD E. · 2010 to 2022
$8.9MNovel Spectinamide Antibiotics for the Treatment of MDR/XDR TuberculosisR44AI098271 · NIAID · MICROBIOTIX, INC · PI BUTLER, MICHELLE M. · 2014 to 2021
$6.0MVectra Polaris microscope imaging systemS10OD030263 · OD · COLORADO STATE UNIVERSITY · PI GONZALEZ-JUARRERO, MERCEDES · 2021 to 2021
$452kHHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) 1S10OD030263HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R01AI090810HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R44AI098271NIAID NIH HHS R01 AI090810NIAID NIH HHS R44 AI098271NIH HHS S10 OD030263
Abstract
The spectinamides are novel, narrow-spectrum semisynthetic analogs of spectinomycin, modified to avoid intrinsic efflux by
Indexed as
Antitubercular AgentsDisease Models, AnimalMycobacterium tuberculosisPyrazinamideRifampinSpectinomycinAnimalsDrug Therapy, CombinationFemaleLungMiceMice, Inbred BALB CTissue DistributionTuberculosisAntitubercular AgentsPyrazinamideRifampinSpectinomycinC3HeB/FeJcaseumdrug combinationsrelapsetuberculosis
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.